Connect with us
Brookfield agreed with Santander and Deutsche Bank to raise €11 billion for Grifols' debt refinancing, potentially Spain's largest syndicated loan. This funding is vital for Brookfield’s...
Grifols achieved its best score in the S&P Global Sustainability ranking with 70 points, improving by seven from last year. The ranking recognized its advancements in...
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....
JPMorgan Chase reduced its stake in Grifols from 3.09% to 2.99% as Brookfield seeks sovereign fund partners for a potential takeover bid. JPMorgan's 12.7 million shares...
Grifols shares rose 2.6% following reports that Canadian firm Brookfield is in informal talks with sovereign funds for a takeover bid. Brookfield is seeking €9.5 billion...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
Moody's withdrew Grifols' ratings, citing "insufficient or inadequate" information amid a potential takeover by family shareholders and Brookfield fund. Grifols' shares dropped, with Class A down...
Grifols can modify its complaint until September 9 or notify by August 13 if it will maintain it. Gotham has until September 12 to respond, Grifols...
Biotest, a Grifols group company, expects $1 billion in US sales of its immunoglobulin drug Yimmugo over the next seven years, following FDA approval. Grifols shares...